We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Nitric Oxide Shown To Cause Colon Cancer

By LabMedica International staff writers
Posted on 12 Feb 2009
Scientists have long established a link between inflammation, cancer, and the compound nitric oxide, which may be produced when the immune system responds to bacterial infections, including those of the colon. More...
However, the precise nature of the relationship was unknown--until now.

Researchers from the Massachusetts Institute of Technology's (MIT; Cambridge, MA, USA) division of comparative medicine and department of biological engineering recently discovered that nitric oxide produced by inflammatory cells during bacterial infection can cause colon cells to become cancerous. This finding suggests that suppressing the compound may help prevent or treat colon cancer, the third most common form of cancer in the United States.

The researchers, led by Dr. James Fox, director of the division of comparative medicine, reported their findings in the January 19, 2008, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS).

Many years ago, it was discovered that gastrointestinal infection by Helicobacter pylori is frequently associated with cancer in humans; a related bacteria called H. hepaticus has similar effects in mice. Nitric oxide is produced during the inflammatory response to such bacterial infection, but it has been unclear whether it was damaging cells or protecting them. By studying the mice, the MIT team revealed that nitric oxide produced by different types of cells has different effects. "Nitric oxide delivered by inflammatory cells, in particular, is important in causing changes in intestinal epithelial cells, setting the stage for cancer development,” said Dr. Susan Erdman, lead research scientist in the division of comparative medicine and lead author of the PNAS article.

In mice infected with H. hepaticus, the researchers found that blocking an enzyme required to generate nitric oxide reduced colon cancer rates. More research is needed to study the exact effects of nitric oxide and develop potential clinical therapies for colon cancer, according to Dr. Erdman. "Therapies will need to be targeted to inhibit the damaging effects of nitric oxide while preserving as many of the protective elements of nitric oxide as possible,” she said.

"This study is a wonderful example of the value and final product that results from an interdisciplinary team effort,” concluded Dr. Fox.

Related Links:

Massachusetts Institute of Technology



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.